Positron emission tomography provides molecular imaging of biological processes

TLDR

PET imaging is a sensitive molecular tool that translates biological processes from in vitro studies to in vivo disease biology. PET whole‑body imaging identifies early disease, differentiates benign from malignant lesions, surveys metastases, and monitors therapy, while microPET systems enable gene‑expression assays from mice to patients and probes are developed simultaneously as imaging agents and drugs. PET detects neurological abnormalities before CT/MRI changes or symptoms appear and improves diagnostic accuracy by 8–43 % over conventional methods, altering treatment in 20–40 % of patients with various cancers.

Abstract

Diseases are biological processes, and molecular imaging with positron emission tomography (PET) is sensitive to and informative of these processes. This is illustrated by detection of biological abnormalities in neurological disorders with no computed tomography or MRI anatomic changes, as well as even before symptoms are expressed. PET whole body imaging in cancer provides the means to (i) identify early disease, (ii) differentiate benign from malignant lesions, (iii) examine all organs for metastases, and (iv) determine therapeutic effectiveness. Diagnostic accuracy of PET is 8-43% higher than conventional procedures and changes treatment in 20-40% of the patients, depending on the clinical question, in lung and colorectal cancers, melanoma, and lymphoma, with similar findings in breast, ovarian, head and neck, and renal cancers. A microPET scanner for mice, in concert with human PET systems, provides a novel technology for molecular imaging assays of metabolism and signal transduction to gene expression, from mice to patients: e.g., PET reporter gene assays are used to trace the location and temporal level of expression of therapeutic and endogenous genes. PET probes and drugs are being developed together-in low mass amounts, as molecular imaging probes to image the function of targets without disturbing them, and in mass amounts to modify the target's function as a drug. Molecular imaging by PET, optical technologies, magnetic resonance imaging, single photon emission tomography, and other technologies are assisting in moving research findings from in vitro biology to in vivo integrative mammalian biology of disease.